Overview

A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3 study is to evaluate the efficacy and safety of Daridorexant compared to in participants with insomnia disorder.
Phase:
PHASE3
Details
Lead Sponsor:
Nxera Pharma Korea Co., Ltd.
Treatments:
daridorexant